MapLight CSO sells 51,707 shares under 10b5-1 plan
MapLight Therapeutics, Inc. Chief Scientific Officer Lillie James Woodruff sold 51,707 shares of Voting Common Stock in open‑market transactions.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
MapLight Therapeutics, Inc. Chief Scientific Officer Lillie James Woodruff sold 51,707 shares of Voting Common Stock in open‑market transactions. The sales occurred on May 4–6, 2026 at prices reported around the high‑$20s to low‑$30s per share, with some trades executed at weighted average prices.
After these transactions, Woodruff directly holds 243,450 shares of Voting Common Stock. The filing states that the trades were made pursuant to a Rule 10b5-1 trading plan adopted on December 29, 2025, indicating they were pre‑scheduled rather than discretionary market‑timed sales.
Insider Trade Summary 10b5-1
Net Seller: 51,707 shares
Net Sell
8 txns
Insider
Lillie James Woodruff
Role
Chief Scientific Officer
Sold
51,707 shs ($1.47M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Voting Common Stock | 8,390 | $28.04 | $235K |
| Sale | Voting Common Stock | 16,421 | $29.13 | $478K |
| Sale | Voting Common Stock | 10,132 | $28.12 | $285K |
| Sale | Voting Common Stock | 963 | $29.00 | $28K |
| Sale | Voting Common Stock | 9,250 | $27.50 | $254K |
| Sale | Voting Common Stock | 5,526 | $28.37 | $157K |
| Sale | Voting Common Stock | 320 | $29.56 | $9K |
| Sale | Voting Common Stock | 705 | $30.08 | $21K |
Holdings After Transaction:
Voting Common Stock — 243,450 shares (Direct)
Footnotes (9)
- F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 to $27.835 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.845 to $28.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.9669 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $28.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.79 to $29.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.675 to $28.6587 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.71 to $29.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Shares sold: 51,707 shares
Post-transaction holdings: 243,450 shares
Sale price example: $27.50 per share
+3 more
6 metrics
Shares sold
51,707 shares
Total Voting Common Stock sold across May 4–6, 2026
Post-transaction holdings
243,450 shares
Voting Common Stock directly held after May 6, 2026 sales
Sale price example
$27.50 per share
One reported open‑market sale price on May 4, 2026
Highest reported sale price
$30.08 per share
One transaction price reported on May 4, 2026
Rule 10b5-1 plan adoption date
December 29, 2025
Date the CSO adopted the trading plan used for these sales
Number of sale transactions
8 transactions
Count of non‑derivative open‑market sale entries in the Form 4
Key Terms
Rule 10b5-1 trading plan, weighted average price, Voting Common Stock, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Voting Common Stock financial
"security_title": "Voting Common Stock""
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did MapLight Therapeutics (MPLT) disclose?
MapLight Therapeutics disclosed that Chief Scientific Officer Lillie James Woodruff sold 51,707 shares of Voting Common Stock. The open‑market sales were executed over May 4–6, 2026 at prices in the high‑$20s to low‑$30s per share, according to the Form 4.
Over what dates did the MapLight (MPLT) insider sales occur?
The insider sales by Chief Scientific Officer Lillie James Woodruff occurred on May 4, May 5, and May 6, 2026. Each day included multiple open‑market transactions in Voting Common Stock, as detailed individually in the Form 4 transaction table.
Were the MapLight (MPLT) insider sales made under a Rule 10b5-1 plan?
Yes. A footnote explains the sales were made pursuant to a Rule 10b5-1 trading plan adopted by Lillie James Woodruff on December 29, 2025. Such plans pre‑schedule trades, which can make transaction timing less indicative of management’s short‑term market views.
What type of security did the MapLight (MPLT) insider sell?
The Form 4 shows that Chief Scientific Officer Lillie James Woodruff sold MapLight Therapeutics Voting Common Stock. All eight reported transactions involve this same security type and are classified as non‑derivative open‑market sales rather than option exercises or other derivative events.
AI-generated analysis. How Rhea-AI works. Not financial advice.
